United Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UTHR research report →
Range $368 – $850
Price Chart
About the company
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity.
- CEO
- Martine A. Rothblatt
- IPO
- 1999
- Employees
- 1,400
- HQ
- Silver Spring, MD, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a strong multi-month uptrend, trading well above both the 50-day and 200-day moving averages. It sits near the upper end of its 52-week range, which keeps the long-term trend constructive even after a recent pullback from the highs.
Street sentiment is constructive, with a Buy consensus and an average target of $671.73, above the last closed price. Recent revisions have leaned higher, including target lifts from Wells Fargo, Raymond James, H.C. Wainwright, and Jefferies, though Goldman Sachs still carries the lone Sell.
The next print comes after a mixed beat pattern, with 4 beats in the last 8 quarters. Estimates still point higher, with next-year EPS at 31.4432 versus 26.49 TTM, so shareholders should watch whether margin discipline and product demand can re-accelerate results after the latest miss.
The pattern is net selling, but most of the activity is automatic award-related movement rather than discretionary conviction. The only clear discretionary signal is a cluster of S-sale transactions by the CEO, while the repeated M-Exempt entries look like equity award vesting or related administrative flows.
Profitability remains elite, led by an 86.3% gross margin and a 38.61% net margin. Revenue grew 4.1% year over year, while EPS growth was down 20.3%, showing that earnings have been choppier than sales despite strong cash generation and a net cash balance of $1.52 billion.
UTHR screens as a premium biotech with stronger margins and cash generation than most specialty drug peers. The setup still carries a valuation premium, with a 21.15 P/E and a consensus target above the current share price, so execution matters more than sector beta.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.63B
- P/E
- 19.64
- Fwd P/E
- 22.50
- PEG
- 112.00
- P/S
- 7.50
- P/B
- 3.82
- EV/EBITDA
- 14.35
- Div Yield
- 0.00%
- Gross Margin
- 86.34%
- Op Margin
- 41.47%
- Net Margin
- 38.61%
- ROE
- 19.18%
- ROIC
- 16.83%
Latest fiscal year · YoY change
- Revenue
- $3.18B+10.6%
- Gross Profit
- $2.80B+9.0%
- Op Income
- $1.52B
- Net Income
- $1.33B+11.7%
- EPS
- $30.13+14.0%
- OCF Growth
- +17.6%
- FCF Growth
- -3.7%
- 52W High
- $614.23
- 52W Low
- $455.63
- 50D MA
- $548.85
- 200D MA
- $539.47
- Beta
- 0.56
- RSI (14)
- 42
- Avg Volume
- 703.53K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
United Therapeutics reported record third-quarter revenue and Tyvaso sales, with management saying commercial momentum has improved, while several pipeline timelines moved later after FDA feedback.· November 4, 2026
- Record Q3 revenue of $833 million and record Tyvaso revenue of $504 million, driven by strong underlying demand and sequential growth.
- Management said Tyvaso momentum improved on better execution, higher referrals, stronger physician engagement, and more patients reaching higher doses.
- The settlement around YUTREPIA removed PH-ILD from that label; management expects only moderate near-term switching, with the bigger opportunity in new PH-ILD prescriptions.
- The soft mist inhaler NDA is now expected in 2027, not by year-end, because additional supporting data is needed.
- Ralinepag remains on track for a June 24 PDUFA date, but the company is working through an API supplier OAI issue and has contingency plans.
United Therapeutics reported third-quarter 2026 record total revenue of $833 million and record Tyvaso revenue of $504 million. Management said Tyvaso growth reflected strong underlying demand, with starts, referrals, dosing, and physician engagement all supporting the quarter. No EPS, gross margin, or year-over-year percentage changes were stated in the transcript. Looking ahead, management said near-term switching from YUTREPIA to Tyvaso should be moderate under the settlement terms, while continued PH-ILD penetration remains the main growth driver. They also said the soft mist inhaler NDA is now expected in 2027 rather than at the end of this year, and ralinepag still has a PDUFA date of June 24 next year.
Martine Rothblatt framed the quarter as evidence of a broader transformation at United Therapeutics, saying the company is building a larger cardiopulmonary and respiratory franchise beyond its pulmonary hypertension legacy. She emphasized a pipeline with 14 programs, long-dated intellectual property, and a strategy of “approve, then improve” through new devices, formulations, and next-generation medicines. Her tone was highly upbeat and long-term focused, with recurring references to scale, durability, and multiple future launches.
James Edgemond highlighted the capital-allocation rationale behind buying down Arena’s economics in ralinepag, saying it reflected confidence in the oral ralinepag revenue opportunity and in future dry-powder inhalation formulations. He described the transaction as an opportunistic use of capital and said the price came out of extensive negotiations, without disclosing the details. He also reiterated the pending oral ralinepag NDA and its June 24 PDUFA date, while noting the company sees value across its inhaled pipeline beyond the current filing.
Analysts focused on how much YUTREPIA patients might switch to Tyvaso after PH-ILD was removed from the YUTREPIA label, and management said no switch is required under the settlement and that patient transitions will be a physician-and-patient decision. Michael Benkowitz said the bigger opportunity is new prescriptions and broader PH-ILD penetration, not forced switching. Questions also centered on the soft mist inhaler timeline and the ralinepag API manufacturer OAI issue; Pat Poisson said the soft mist NDA now needs additional data and is expected in 2027, while the API compliance issue is being remediated with contingency plans in place. Management also explained that the triple oral pill is effectively on hold while they explore alternative filing paths with FDA.
The company delivered its best quarter ever on a revenue basis, with record total revenue and Tyvaso sales, and management said the commercial engine is now showing more consistent month-to-month performance. They also pointed to stronger referrals, improved dosing, and an expanded field force as evidence that momentum is carrying into Q4 and next year. Management remained confident in multiple future catalysts, including ralinepag and the soft mist and dry-powder inhalation programs.
Several development timelines slipped or remain uncertain: the soft mist inhaler NDA moved out to 2027, and the triple oral pill is paused while the company looks for an FDA-acceptable alternate path. Ralinepag also has execution risk from the API supplier’s OAI status, even though management says it has contingencies. On the commercial side, management said near-term YUTREPIA-to-Tyvaso switching should be only moderate, so part of the growth story still depends on continued new prescription gains rather than immediate conversion volume.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.4%
- Shares Outstanding
- 42.59M
- Float Shares
- 38.91M
of shares held by institutions
903 13F filers
Buy/sell ratio 0.07. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for UTHR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 12, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 12, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Mar 1, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Mar 1, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 28, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 28, 22 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Mar 6, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.58M | ▲ 280.63K |
| Vanguard Group Inc | 4.18M | ▼ 242.59K |
| Avoro Capital Advisors LLC | 2.78M | ▲ 147.78K |
| State Street Corp | 1.95M | ▲ 54.49K |
| Vanguard Capital Management LLC | 1.93M | ▲ 10.67K |
| Vanguard Portfolio Management LLC | 1.91M | ▼ 7.90K |
| Renaissance Technologies LLC | 1.68M | ▼ 32.84K |
| Wellington Management Group Llp | 1.38M | ▼ 885.22K |
| Amundi | 988.82K | ▲ 769.73K |
| Geode Capital Management, LLC | 974.99K | ▼ 21.61K |
| Janus Henderson Group Ltd. | 866.93K | ▲ 70.83K |
| Jupiter Topco LLC | 831.13K | ▲ 831.13K |
Held by 1,336 ETFs
Biggest fund positions in UTHR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | MAHON PAUL A | other | 8,300 |
| Nov 19, 26 | MAHON PAUL A | sell | 440 |
| Nov 19, 26 | MAHON PAUL A | sell | 1,240 |
| Nov 19, 26 | MAHON PAUL A | sell | 523 |
| Nov 19, 26 | MAHON PAUL A | sell | 378 |
| Nov 19, 26 | MAHON PAUL A | sell | 400 |
| Nov 19, 26 | MAHON PAUL A | sell | 197 |
| Nov 19, 26 | MAHON PAUL A | sell | 300 |
| Nov 19, 26 | MAHON PAUL A | sell | 76 |
| Nov 19, 26 | MAHON PAUL A | sell | 69 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UTHR coverage
Recent articles, reports, and earnings notes.

United Therapeutics (UTHR): Tyvaso Growth Meets Pipeline Catalysts
United Therapeutics combines a cash-rich balance sheet with record Tyvaso sales and multiple late-stage catalysts, but concentration in its flagship franchise keeps execution risk elevated. The stock looks fairly valued for a high-quality specialty biopharma with meaningful upside tied to 2027 regulatory decisions.

United Therapeutics Corporation (UTHR) gains on deep earnings analysis
United Therapeutics Corporation (UTHR) posted a mixed quarter, missing EPS but beating revenue as shares gained on the session. This deep-dive looks beyond the headline, examining record Tyvaso sales, the Liquidia settlement, margin pressure, pipeline breadth, and why investors focused on growth over the earnings miss.

United Therapeutics Corporation (UTHR) gains after earnings misses
United Therapeutics Corporation (UTHR) gains 0.3% even as earnings miss expectations, with investors weighing the latest results against the company’s outlook and pipeline progress.
Want a deeper read on UTHR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease
businesswire.com · Nov 20
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,627,990.00 in Stock
defenseworld.net · Nov 19
Commonwealth Equity Services LLC Purchases 1,695 Shares of United Therapeutics Corporation $UTHR
defenseworld.net · Nov 18
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
marketbeat.com · Nov 16
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
zacks.com · Nov 16
United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
5,137 United Therapeutics Corporation $UTHR Shares Purchased by Fisher Asset Management LLC
defenseworld.net · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice